NCT00230347已完成1 期
Dose Escalation Study Evaluating Stereotactic Radiosurgery for Liver Malignancies
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Efficacy of radiosurgical ablation of liver tumors, in terms of radiographic response
研究概览
简要总结
This study is intended to establish the practicality of treating cancer in the liver with precisely administered single fractions of high-energy radiation using a radiosurgical (cross-firing) technique. A second purpose is to establish a safe dose for such therapy. Finally, the efficacy of radiosurgical ablation of liver tumors, in terms of radiographic response, will be measured.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All the following criteria must be met:
- •Liver tumors not to exceed 5 cm in diameter. If this size can be increased at all, that would be beneficial as many liver lesions present at a larger size given the lack of symptoms until they are larger and adequate hepatic function with albumin >3.0, total bilirubin <3, INR 1.
- •In the case of patients with known or 7 Dose Escalation Study Evaluating Stereotactic Radiosurgery for Liver Malignancies suspected cirrhosis, patients must have creatinine <1.5 and cannot have uncontrolled ascites, encephalopathy, active or recent gastrointestinal bleed (GIB).
- •Age > 18 years old
- •Histologically confirmed hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (IHCC), or metastatic adenocarcinoma of the breast/colon. Metastatic tumors of other histologic types or sites of origin may be included if the patients have a life expectancy of 6 months or greater. In the case of suspected HCC in patients with known cirrhosis, noninvasive criteria recommended by the European Association for the Study of Liver Diseases may be used. Hypervascular lesions > 2cm with alpha-fetoprotein (AFP) > 400ng/mL or hypervascular lesions >2cm on at least 2 imaging studies.
- •Unresectable disease as determined by a surgeon
- •Eastern Clinical Oncology Group performance status 0,1 or 2
- •No chemotherapy within 1 month of registration
- •No prior radiotherapy to the liver or upper abdominal area
- •Life expectancy > 6 months
- •Patients with IHCC or HCC with distant metastasis are not eligible for this study.
- •For colon cancer patients with metastatic tumor of the liver who are not amenable to surgical resection due to the efficacy of removal of simultaneous lung and liver metastasis.
排除标准
- •Children are excluded because HCC, IHCC, and hepatic metastases rarely occur in this age group. Furthermore, treatment requires a great deal of patient cooperation including the ability to lie still for several hours in an isolated room.
- •No laboratory personnel will be included.
结局指标
主要结局
Efficacy of radiosurgical ablation of liver tumors, in terms of radiographic response
Practicality of treating cancer in the liver with precisely administered single fractions of high-energy radiation using a radiosurgical (cross-firing) technique
Safe dose for therapy
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Metastatic Tumors to the LiverLiver CancerNCT01030757New Mexico Cancer Care Alliance2
招募中
1 期
Stereotactic Radiosurgery Dose Escalation for Brain MetastasesBrain MetastasesNCT02390518University of Utah86
招募中
不适用
Comparison of Efficacy in SBRT of Large HCC With or Without TACELarge HCC PatientsTranscatheter Arterial ChemoembolizationStereotactic Body Radiation TherapyNCT04512846Beijing 302 Hospital100
招募中
不适用
Stereotactic Radiosurgery in Patients With Head and Neck Region TumoursHead and Neck CancerNCT06472570Maria Sklodowska-Curie National Research Institute of Oncology80
已完成
不适用
Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer (RAD 1203)Radiation ToxicityProstate AdenocarcinomaSexual DysfunctionProstate CancerNCT01856855John Fiveash, MD26